Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) rose 2.1% during trading on Tuesday . The stock traded as high as C$3.00 and last traded at C$2.92. Approximately 12,654 shares changed hands during trading, an increase of 71% from the average daily volume of 7,410 shares. The stock had previously closed at C$2.86.
Eupraxia Pharmaceuticals Stock Up 2.1 %
The company’s 50 day moving average price is C$3.33 and its two-hundred day moving average price is C$3.93.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Garmin Navigates to New Highs Driven By Wearables Trend
- What Are Dividend Contenders? Investing in Dividend Contenders
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
